ak001
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02563938)
Timeline
Indications
Mechanism of action
- Sialic acid-binding Ig-like lectin 8INHIBITOR
SIGLEC8 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ak001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02734849 | Phase 2 | Apr 1, 2016 | Allakos, Inc., Ghent University |
| NCT02563938 | Phase 1 | Sep 1, 2015 | Allakos, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allakos, Inc. | For profit | 2 | 2 | 2 | 2015 |
| Ghent University | Academic/Hospital | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1